MEDINCELL SA (MEDCL.PA) Stock Price, Forecast & Analysis
Europe • Euronext Paris • EPA:MEDCL • FR0004065605
MEDCL.PA Key Statistics, Chart & Performance
The current stock price of MEDCL.PA is 23.42 EUR. In the past month the price decreased by -8.73%. In the past year, price increased by 48.23%.
MEDCL.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MEDCL.PA. When comparing the yearly performance of all stocks, MEDCL.PA turns out to be only a medium performer in the overall market: it outperformed 69.51% of all stocks.
MEDCL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MEDCL.PA. The financial health of MEDCL.PA is average, but there are quite some concerns on its profitability.
MEDCL.PA Financial Highlights
Over the last trailing twelve months MEDCL.PA reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 43.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MEDCL.PA Forecast & Estimates
17 analysts have analysed MEDCL.PA and the average price target is 35.99 EUR. This implies a price increase of 53.69% is expected in the next year compared to the current price of 23.42.
For the next year, analysts expect an EPS growth of 59.91% and a revenue growth 13.44% for MEDCL.PA
MEDCL.PA Ownership
MEDCL.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.69 | 197.812B | ||
| SAN | SANOFI | 9.59 | 197.667B | ||
| SNW | SANOFI | 9.67 | 197.353B | ||
| MRK | MERCK KGAA | 14.2 | 53.847B | ||
| UCB | UCB SA | 26.08 | 51.837B | ||
| UNC | UCB SA | 25.09 | 50.184B | ||
| 1BAYN | BAYER AG-REG | 9.24 | 44.371B | ||
| BAYN | BAYER AG-REG | 9.17 | 44.356B | ||
| IPN | IPSEN | 11.89 | 11.465B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.082B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find more growth stocks the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About MEDCL.PA
Company Profile
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 145 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Company Info
MEDINCELL SA
3 Rue des Freres Lumiere
Jacou OCCITANIE FR
Employees: 131
Phone: 33467021367
MEDINCELL SA / MEDCL.PA FAQ
What does MEDINCELL SA do?
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 145 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Can you provide the latest stock price for MEDINCELL SA?
The current stock price of MEDCL.PA is 23.42 EUR. The price increased by 2% in the last trading session.
Does MEDCL stock pay dividends?
MEDCL.PA does not pay a dividend.
What is the ChartMill rating of MEDINCELL SA stock?
MEDCL.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is MEDINCELL SA worth?
MEDINCELL SA (MEDCL.PA) has a market capitalization of 775.90M EUR. This makes MEDCL.PA a Small Cap stock.